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Background: Complementary therapies are widely used among cancer patients. Kuan-Sin-Yin (KSY) decoction, a
popular qi-promoting herbal medicine, was constituted with several herbs known to exhibit immunomodulating or
anticancer activity. After combining these herbs as a compound formula, it is necessary to reassess the
immunomodulation effects, the effects on tumor growth, and possible toxicity of KSY.
Methods: The anti-cancer effects of KSY in vivo were determined by measuring the tumor volumes, anticancer-
associated cytokines (IFN-gamma, TNF-alpha, IL-2, and IL-12), accumulation of tumor infiltrating leukocytes (TILs),
proliferation and apoptosis-related molecular markers (Ki-67, p53, p21, activated caspase 3, and cleaved PARP), and
an in situ TUNEL assay. The body weight and serum chemistry of treated mice were also assessed. In vitro, the
effects of KSY were evaluated using MTT assay, BrdU incorporation assay and cell growth curve.
Results: In vivo, KSY suppressed bladder or lung cancer growth but did not promote the production of cytokines
nor increase the accumulation of TILs. The expression of p53 and p21 in KSY-treated mice were increased. The
numbers of apoptotic tumor cells and the expression of apoptosis marker proteins (Caspase 3 and cleaved PARP)
were not significantly elevated after KSY treatment. In vitro, the viability and proliferation of tumor cells, but not
normal cells, were suppressed by KSY treatment. No significant toxicity was found in KSY-treated mice.
Conclusions: KSY suppressed the tumor growth in vivo and in vitro, which resulted from its cytostatic effects on
cancer cells, rather than the induction of anti-cancer immunity. Under these experimental conditions, no apparent
toxicity was observed.
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Cancer is the leading cause of death worldwide. Tumor
cells have developed a variety of strategies to survive and
suppress anti-tumor immune response. The conventional
treatments such as surgery, radiotherapy, and chemother-
apy impair the patient’s immunity [1]. When the immune
system is not working well, the frequent infections or
chronic inflammation status might contribute to chronic
fatigue and tumor progression or recurrence. On the other
hand, micrometastases of cancer stem cells frequently lead* Correspondence: owlherbs@yahoo.com.tw; slfu@ym.edu.tw
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Within the cancer patient population, complementary
and alternative medicine (CAM) is used widespread and
estimated to be as high as 64% [3]. It was expected that
CAM options could relieve the general illness or undesir-
able side effects, stimulate and protect immunity, or pre-
vent further tumor progression or recurrence [4-7]. In
Taiwan, the use of traditional Chinese medicine (TCM)
has been reimbursed by the National Health Insurance
since 1996. More than 60% of outpatients obtained from
the National Health Insurance database (NHIRD) had
used TCM from 1996-2001 [8]. TCM is very popular in
Taiwan, including fighting the related symptoms of malig-
nant neoplasm.is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Li et al. BMC Complementary and Alternative Medicine 2014, 14:488 Page 2 of 12
http://www.biomedcentral.com/1472-6882/14/488A compound herbal formula, Kuan-Sin-Yin (KSY) de-
coction had been used to “reinforce the healthy qi” in
traditional Chinese medicine (TCM) theory and it was
widely used to treat the dysfunctional gastrointestinal
symptoms and chronic fatigue syndrome. In clinical trial
study, KSY improved the score on the physical component
of the World Health Organization Quality of Life-Brief
Version (WHOQOL-BREF) of hepatitis B virus carriers
[9]. Individual purified compounds and herbal extracts in
KSY have been previously demonstrated to exhibit immu-
nomodulatory or anti-cancer effects in vivo and in vitro
[10-19]. Astragalus membranaceus and Codonopsis pilo-
sula, which are ingredients of KSY, were reported that
they could function as adjuvant therapies during chemo-
therapy and radiation therapy in clinical trials [1,20-22].
Current observations indicate that KSY might function
as an immunomodulator to suppress tumor growth and
as a complementary cancer therapy. However, as a com-
pound formula, these expected therapeutic effects of
KSY are rarely studied. In this study, the effects of KSY
on immunomodulation and tumorigenesis, as well its




ide (MTT), lipopolysaccharide (LPS), phytohemagglutinin
(PHA), 4’,6-diamidino-2-phenylindole (DAPI), 5-bromo-2’-
deoxyuridine (BrdU) were purchased from Sigma Chemical
Co. (St. Louis, USA). Lipo-Dox (doxorubicin hydrochlor-
ide) was purchased from TTY Biopharm Co. (Taipei,
Taiwan); OK-432 (Picibanil) was acquired from Chugai
Pharmaceutical (Tokyo, Japan).
Preparation of KSY
To prepare the KSY, concentrated aqueous extracts of
seven Chinese herbs were mixed in fixed ratios (shown in
Table 1) and boiled in 500 ml sterile water for 30 minutes.
The aqueous extracts of the raw ingredients of KSY wereTable 1 Ingredients in KSY
Medicinal plants Portions used Ratio
Dan Shen Dried roots of Codonopsis pilosula (Franch.)
Nannf.
2
Fu Ling Dried sclerotium ofthe fungus, Poria cocos
(Schw.) Wolf
2
Bai Zhu Rhizome of Atractylodes macrocephala Koidez. 2
Gan Cao Dried roots and rhizome of Glycyrrhiza
uralensis Fisch.
1
Nu Zhen Zi Dried fruits of Ligustrum lucidum Ait. 1
Huang Qi Dried roots of Astragalus membranaceus
(Fisch.) Bunge.
2
Guan huo xiang Dried branches and leaves of Pogostemon
cablin (Blanco) Bench.
2provided by the manufacturer, Sun-Ten Pharmaceutical
Co. Ltd. (Taipei, Taiwan). The amounts of heavy metals,
residual pesticides and microbes in each herb were
inspected and met the safety criteria of Taiwan Food and
Drug Administration (TFDA). The final concentration
was defined as the weight of the aqueous herbal mixtures
(152.3 g) in 500 ml of ddH2O, which was approximately
0.3 g/ml. For in vitro experiments, a quantified amount
(15 ml) of the KSY extract was processed with a freeze-
dryer to obtain crystal powder (0.87 g), which was then re-
dissolved in sterile ddH2O, filtered and stored as a stock
solution (100 mg/ml) at -20°C. The protocol regarding
HPLC analysis of KSY was described in the supplementary
section “Additional file 1”.
Cell lines and culture conditions
The mouse bladder carcinoma cell line MBT-2 (obtained
from Dr. Lih-Hwa Hwang, National Yang-Ming Univer-
sity, Taiwan), the mouse Lewis lung carcinoma line LLC-
1 (American Type Culture Collection; Manassas, USA)
and the primary mouse embryo fibroblast MEF cell line
(obtained from Dr. Ting-Feng Tsai, National Yang-Ming
University, Taiwan) were cultured in Dulbecco’s modi-
fied Eagle medium (Invitrogen, CA, USA) supplemented
with 10% heat-inactivated fetal bovine serum (FBS), 100
units/ml penicillin, 100 μg/ml streptomycin and 2 μM
L-glutamine in a humidified 5% CO2 incubator at 37°C.
Animals
C3H/HeN, BALB/cAnN-Foxn1nu/Cr1Nar1, and C57BL/
6 mice were purchased from the National Laboratory
Animal Center (Taipei, Taiwan) and maintained at the
Animal Center of Yang-Ming University (Taipei, Taiwan)
following the Guidelines for the Care and Use of Labora-
tory Animals (National Institutes of Health, USA). All
experiments utilizing mice were approved by the Institu-
tional Animal Care and Use Committee (IACUC Ap-
proval No. 1001246) at National Yang-Ming University
(Taipei, Taiwan).
Mouse tumor models and treatment protocols
Treatment protocols in three different mouse tumor
models were used in this study, which are outlined in
Figure 1. In all models, cancer cells (1 × 106) were injected
s.c. into the dorsum of mice. The tumor volume (V) was
calculated by the following formula: V = 1/2(L ×W2),
where L is the length and W is the width of tumor. After
tumor volumes reached 100 ± 20 mm3 (~10 days), mice
were randomly assigned into different drug treatment
groups (Figure 1, day 0).
For the bladder tumor model in immunocompetent
mice (Figure 1, C3-B), MBT-2 bladder cancer cells were
inoculated into C3H/HeN mice, and the mice were ran-
domly divided into three different treatment groups: the
Figure 1 Outline of tumor models and treatment protocols used in this study. (Upper panel) treatment protocols and administration routes
for different drugs. KSY: 1000 mg/kg/day, p.o.; OK-432: 4 mg/kg per injection, i.p.; Lipo-Dox: 1.5 mg/kg per injection, i.v.. (Bottom panel) tumor
mouse models used in this study. In the C3-B model, C3H/HeN mice were injected with a syngeneic bladder cancer cell line MBT-2. In the Nu-B
model, BALB/cAnN-Foxn1nu/Cr1Nar1 mice were inoculated with MBT-2 cells. In the B6-L model, C57BL/6 mice were injected with a syngeneic
lung cancer cell line LLC-1. The detailed experimental procedures are described in the “Methods”.
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treated group. OK432 is a Streptococcal immunotherapeu-
tic agent used as the positive control. The KSY-treated
group received KSY treatments (1000 mg/kg/day, p.o.).
The OK432-treated group received OK-432 treatments
(4 mg/kg, i.p.) on days 0, 2, 4, 6, 9, and 12.
For the bladder tumor model in immunocompromised
mice (Figure 1, Nu-B), the nude mouse strain BALB/
cAnN-Foxn1nu/Cr1Nar1 were inoculated with MBT-2
bladder cancer cells and divided into three treatment
groups: the KSY-treated group, the vehicle group and
the liposome-doxorubicin (Lipo-Dox)-treated group. The
cytotoxic chemotherapeutic drug liposome-doxorubicin
was used as the positive control. The KSY-treated group
received KSY (1000 mg/kg/day, p.o.). For the Lipo-
Dox-treated group, the tumor-bearing mice were injected
with Lipo-Dox (1.5 mg/kg in PBS i.v.) on days 0 and 7.
The vehicles for the KSY, OK-432, and Lipo-Dox
groups were ddH2O, PBS, and PBS, respectively. The
KSY dosage used in this study was referred from that
used in clinical study described previously [9].
For the lung cancer model (Figure 1, B6-L) in immuno-
competent mice, LLC-1 lung cancer cells were inoculated
into the syngeneic C57BL/6 mouse strain. The experimen-
tal treatment protocol was similar to the Nu-B model
protocol described above. For the co-treatment group
combining KSY with Lipo-Dox, tumor-bearing mice were
injected Lipo-Dox (1.5 mg/kg in PBS) i.v. on day 0 and 7,
and at the same time, they were given KSY (1000 mg/kg/
day) p.o. daily.Cytokine production measurements
The tumor tissues were lysed with protein extraction
buffer (50 mM Tris-HCl, pH 7.4, 15 mM NaOH, 0.1%
NP-40, 5 mM EDTA, and 10 mM EGTA) containing
protease inhibitors (Sigma-Aldrich). The concentrations
of cytokines in the tumor lysates (500 μg) were mea-
sured by ELISA kits (R&D Systems, Minneapolis, USA).
Primary splenocytes were isolated from the treated mice
as previously described [23], and then 3 × 106 spleno-
cytes from each treated mouse were cultured and stimu-
lated with the T cell mitogen PHA for 72 h. Afterwards,
the supernatants from the splenocytes were collected to
measure the cytokine concentrations.
Splenocyte-conditioned medium (SCM)-mediated
cytotoxicity assay
The splenocytes (1.5 × 107) were cultured for 48h with
PHA and the culture medium was collected as splenocyte-
conditioned medium (SCM). Next, MBT-2 cells (2 × 105)
were incubated with the SCM for an additional 48 h. The
SCM-mediated cytotoxicity of MBT-2 cells was measured
as previously described using propidium iodide (PI, 20
μg/ml) and a FACS Calibur flow cytometer (BD Biosci-
ences, NJ, USA) [24].
Quantitative Reverse Transcription Polymerase Chain
Reaction (qRT-PCR)
The protocols for isolation of total RNA from tumor tis-
sues and synthesis of cDNAs have been previously de-
scribed [24]. The primer sequences used in this study
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GAPDH mRNA level was used as the internal control. All
PCR reactions were performed using an Applied Biosys-
tems model 7000 instrument (Applied Biosystems, Califor-
nia, USA).
TUNEL assay
The apoptotic cells in paraffin-embedded tumor sections
were detected with an in situ cell death detection kit
based on the labeling of DNA strand breaks (Roche
Diagnostics, Mannheim, Germany). The tumor sections
were counterstained with DAPI and analyzed by fluores-
cence microscopy (Olympus BX61, Tokyo, Japan). The
image processing and analysis were carried out using the
MetaMorph® Software (Molecular Devices, Inc., California,
USA).
Immunohistochemistry
Paraffin-embedded tumor sections (3 μm) were soaked
in an antigen retrieval buffer containing 10 mM sodium
citrate (pH 6.0) and treated twice with microwave irradi-
ation (650 W) for 10 min. An antibody against Ki-67
(BD, California, USA) was incubated with the tumor
sections overnight. After washing with PBS, the tumor
sections were incubated with biotinylated secondary
antibodies and an avidin/streptavidin-based detection
system (Vectastain® Elite® ABC peroxidase kit, Vector la-
boratories, lnc., Burlingame, USA), followed by treat-
ment with a 3, 3’-diaminobenzidine tetrahydrochloride
(DAB) staining system (Merck Millipore, Billerica, MA,
USA) and counterstaining with hematoxylin. The stained
sections were imaged using a microscope (Olympus BX61,
Tokyo, Japan).
Immunoblotting
The tumor tissues were lysed with a protein extraction
buffer containing protease inhibitors. Protein lysate (50 μg)
from each sample was assessed for the expression of p53,
p21, Caspase-3, PARP or GAPDH as previously described
[25]. Band intensities were quantified using the Image J
program, version 1.40 (NIH, Bethesda, USA).
MTT assays
To measure cell viability, MBT-2 (3 × 103), LLC-1 (1 × 103)
and MEF (3 × 103) cells were cultured in 96-well plates
overnight, treated with the vehicle (sterile ddH2O), KSY
extract, or doxorubicin for 24, 48, and 72 h. Cellular meta-
bolic activity was measured by MTT-based colorimetric
assays as previously described [26].
Growth curve and BrdU incorporation assay
To establish a growth curve, MBT-2 cells (1 × 105) were
cultured overnight and treated with vehicle (sterile
ddH2O), KSY, or lipo-dox for 24, 48, and 72 h. Adherentand floating cells were both collected, and the number
of viable cells was counted by trypan blue dye exclusion.
For BrdU incorporation assays, MBT-2 cells (1 × 105)
were cultured overnight and synchronized by 24 h of
growth in serum-free medium. The serum-starved cells
were incubated with vehicle or drugs for 22 and 46 h
and treated with 10 mΜ BrdU for 2 h, and then both
the adherent and floating cells were collected. The har-
vested cells were fixed in 4% (w/v) buffered-formaldehyde
in PBS, permeabilized with 0.5% Triton X-100 in PBS,
and treated with DNase I. After incubating with an anti-
BrdU antibody (BD, California, USA) and a fluorescein-
conjugated secondary antibody (Jackson ImmunoResearch
Laboratories, Inc., PA, USA), the cells were treated with
RNase (20 μg/ml), stained with PI (20 μg/ml), and then
analyzed by flow cytometry.Blood chemistry measurements
Blood samples were collected from mice under terminal
anesthesia through cardiac punctures. Clear serum samples
were prepared and measured with a Fuji Dri-Chem Clin-
ical Chemistry Analyzer FDC 3500 (Norsted, Germany).Statistical analysis
All data are presented as the mean ± SEM (standard
error of mean) and are from at least three independent
experiments. The Mann-Whitney U test was used to de-
termine the significance of the between-group differences.
Statistical significance was set at p < 0.05. All p values were
two-tailed, and all statistical analyses were performed with
the SPSS statistics software (Statistical Product and Ser-
vice Solutions, IBM, New York, USA).Results
The KSY dosage used in animal experiments is re-
ferred to the clinical dose for human subjects [9]. The
human dosage of KSY was translated to mouse dosage
(~1500 mg/kg) using a formula described previously
[27]. After preliminary toxicity/efficacy experiments, the
dosage of 1000 mg/kg was chosen for subsequent in vivo
experiments.The HPLC analysis of KSY
The HPLC chromatogram of KSY was shown in Additional
file 3: Figure S1 and marker compounds (glycyrrhizic
acid, liquiritin, liquiritin apioside, and calycosin-7-O-β-
D-glucoside) were well resolved by gradient elution. Ana-
lysis showed that 1 g KSY contained 29.59 ± 0.78 μg of
calycosin-7-O- β-D-glucoside, 187.08 ± 4.28 μg of liquiri-
tin apioside, 228.42 ± 2.91 μg of liquiritin, and 701.19 ±
7.92 μg of glycyrrhizic acid.
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immunocompromised mice
To investigate the effect of KSY treatment on tumor de-
velopment, the growth of the MBT-2 bladder cancer
cells in immunocompetent and immunocompromised
hosts (Figure 1, C3-B and Nu-B, respectively) was exam-
ined. The tumor volumes of the KSY- and OK432-
treated mice were reduced compared with the vehicle
group in the C3-B model (Figure 2a). Similar suppressive
effects were observed in the KSY- and Lipo-Dox-treated
groups in the Nu-B model (Figure 2b).
KSY does not induce anticancer immunity
In the C3-B mouse model, the expression of the
anticancer-associated cytokines (TNF-α, IFN-γ, IL-2, and
IL-12) were measured by ELISA assay in the host spleen
and the local tumor area. The result showed that KSY
did not increase the expression of these cytokines in the
tumor area, as compared with the vehicle treatment
(Figure 3a). Furthermore, the cytokine levels secreted
from splenocytes isolated from KSY-treated mice, in the
presence of PHA, were similar to that in vehicle groups
(Figure 3b). Conversely, the TNF-α, IFN-γ and IL-12 se-
cretions were increased in splenocytes of the OK-432
group (Figure 3b). The SCM-driven cytotoxicity of
MBT-2 cells correlated with splenocyte cytokine expres-
sion, as the SCM-mediated cytotoxicity was significantly
enhanced in the OK-432 group but not in the KSY group
(Figure 3c).
The histological examination was next performed. The
tumor-infiltrating leukocytes were significantly elevated
in the tumors of OK-432-treated mice, but not in the
KSY group and vehicle group (Figure 3d). Consequently,
the amounts of tumor-infiltrating leukocytes after KSY
treatment were determined by measuring of the mRNA
expression levels of various immune cell markers. KSY
treatment did not promote the recruitment of immune
cells (i.e., CD4+ T cells, CD8+ T cells, dendritic cells, NKFigure 2 KSY delays tumor growth in both immunocompetent and im
injected s.c. into the dorsum of mice. After 10 days, tumor-bearing mice w
using the treatment protocol described in Figure 1. The mean tumor volum
model (n = 17-20 for each group); (b) The Nu-B model (n = 14 for each grocells and macrophages) at tumor sites, but Ok-432 in-
deed elevated local immune cells (Figure 3e).
KSY treatment reduces proliferation of cancer cell in vivo
The Ki-67 expression was measured by IHC in the tumor
tissues in Nu-B mouse model. As shown in Figure 4a, the
Ki-67 expression was significantly lower in both the Lipo-
Dox- and KSY-treated groups compared with the vehicle
group. Furthermore, the expression levels of cell cycle reg-
ulators, p53 and p21, in tumor tissues were elevated in the
KSY group. The p53 expression of Lipo-Dox group was in-
creased compared with the vehicle group (Figure 4b).
KSY treatment does not increase tumor cell apoptosis
in situ
The apoptotic tumor cells were visualized by an in situ
TUNEL assay. KSY treatment did not enhance the tumor
cell apoptosis (Figure 5a), and this observation was con-
firmed by the expression patterns of activated caspase 3
and cleaved PARP in the tumor tissues (Figure 5b).
In vitro KSY treatment causes cytotoxicity on cancer cells
but not on normal cells
The cancer cell viability was examined by an MTT assay
in vitro. As shown in Figure 6a, the KSY treatments reduced
the viability of MBT-2 tumor cells in a concentration- and
time-dependent manner. Under the same experimental
conditions, KSY treatments did not cause significant
cytotoxicity on primary mouse embryonic fibroblasts
(MEFs), but doxorubicin treatment reduced MEF viability
(Figure 6b).
In vitro KSY treatment suppresses the proliferation of
MBT-2 cells
As shown in Figure 6c, KSY treatment at 1500 μg/ml or
2000 μg/ml for 72 h significantly suppressed the proliferation
of MBT-2 cells in a concentration-dependent manner.
The DNA synthesis ability was further analyzed by BrdU/munocompromised mice. The MBT-2 cancer cells (1 × 106) were
ere randomly grouped and treated with vehicle or indicated drugs
es of treated mice on the indicated days are shown. (a) The C3-B
up). *indicates p < 0.05 versus the vehicle group.
Figure 3 (See legend on next page.)
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Figure 3 KSY neither enhances the secretion of anticancer-associated cytokines, nor increases the recruitment of tumor-infiltrating
leukocytes in tumor-bearing mice. The anticancer immunity in the bladder cancer model (C3-B model in Figure 1) was evaluated. (a) The
expressions of indicated cytokines in tumor tissues were measured by ELISA. (b) The splenocytes (3 × 106/ml) from each treatment group were
cultured in the presence of PHA (5 μg/ml) for 72 h, and the amount of cytokines in the culture medium were measured by ELISA. (c) The culture
medium collected from the splenocytes of drug-treated mice (splenocyte-conditioned medium; SCM) was incubated with MBT-2 cells for 48 h.
The death of MBT-2 cells was detected by PI stain and analyzed by flow cytometry. # indicates undetectable. *indicates p < 0.05 versus the
vehicle group. n = 18-21. (d) Tumor tissues from each treatment group in C3-B model were fixed, sectioned and stained with hematoxylin and
eosin (H&E stain) for microscopic examination. (e) The expression of various immune cell maker genes in tumor tissues of C3-B model mice was
measured using qRT-PCR. CD4: T helper cells; CD8: cytotoxic T cells; CD11b: macrophages; CD11c: dendritic cells; NK1.1: NK cells. Three independent
experiments were performed (n = 3 for each group). *indicates p < 0.05 versus the vehicle group.
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to a 24-h KSY treatment, the percentage of BrdU-positive
cells (S phase) was significantly reduced (Figure 6d). This
reduction of S-phase cells was more evident after longer
treatment (48 h) with higher concentrations of KSY (1500
or 2000 μg/ml) (Additional file 4: Figure S2).Figure 4 In vivo KSY treatment reduces Ki-67 expression and increases
cells (brown) in tumors were detected by immunohistochemistry. Five fixed fi
Ki-67-positive cells. The percentage of Ki-67-positive cells was calculated by th
The quantification of the percentage of Ki-67-positive cells is shown in the low
Nu-B model were detected by Western blot. The quantification data are showThe toxicity assessment of in vivo KSY treatment in
immunocompetent tumor-bearing mice
The body weight, hepatic and renal function were mea-
sured in C3-B model. The serum levels of alanine amino-
transferase and aspartate aminotransferase (AST) were
measured as an index of hepatic function, and the levels ofthe expression of p53 and p21. (a) In the Nu-B model, Ki-67-positive
elds from each tumor section were analyzed for the number of
e number (Ki-67-positive cells/the total cell number of five fields) × 100%.
er panel. (b) The protein expression levels ofp53 and p21 in tumors of
n in the left panel. *indicates p < 0.05 versus the vehicle group.
Figure 5 KSY treatment does not increase tumor cell apoptosis. (a) In the Nu-B model, the apoptotic cells (green) were detected by a TUNEL
assay. Five independent fields from each tumor tissue section were analyzed for the numbers of TUNEL-positive cells. The percentage of apoptotic
cells is shown in the bottom panel and was determined by the following equation: (the number of apoptotic cells/the total cell number of five
fields) × 100%. (b) In the Nu-B model, the expression levels of active caspase 3 and cleaved PARP in tumor tissues were measured by Western
blot. The quantification data are also shown. *indicates p < 0.05 versus the vehicle group.
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index of renal function. No difference in these parameters
was observed between the KSY and control groups, demon-
strating the safety of KSY administration in tumor-bearing
mice under this treatment protocol (Figure 7a and b).The therapeutic and toxicity effects of KSY in a lung
cancer model
To evaluate whether in vivo KSY treatment could sup-
press other type of malignant tumor, a syngeneic lung
cancer mouse model was used (Figure 1, B6-L model).
Figure 6 In vitro KSY treatment decreases cancer cell viability, suppresses proliferation, and interferes with cell cycle progression.
(a) The viability of MBT-2 cancer cells (3,000 cells/well in a 96-well plate) was determined by an MTT assay after a 24, 48, or 72 h vehicle or drug
treatment at indicated concentrations. Doxorubicin (Lipo-Dox) served as the positive control. (b) An MTT assay was also used to measure the
viability of primary MEF cells (3,000 cells/well in a 96-well plate). (c) MBT-2 cancer cells (1 × 105) were treated with different concentrations of KSY
for 24, 48 or 72 h, and the viable cells were determined using Trypan blue exclusion assays. Doxorubicin (Lipo-Dox) served as the positive control.
(d) MBT-2 cells (1 × 105) were treated with different concentrations of KSY for 24 h and then analyzed with BrdU/PI staining and flow cytometry.
Representative FACS dot plots are shown in the left panel, and DNA synthesis (S phase) was determined by quantifying the BrdU-positive cells in
the dot plot. Quantification data of BrdU-positive cells are shown in the right panel. *indicates p < 0.05 versus the vehicle group.
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rubicin was performed to assess the chemosensitizing ef-
fect of KSY. As shown in Figure 8a, the tumor volumes
in mice treated with KSY, Lipo-Dox, and co-treatment
were significantly reduced compared with the vehicle
group, revealing the tumor suppression activity of KSY in
this model. However, there was no difference on tumor
growth between the combined treatment group and
Lipo-Dox group.
The toxicity effects in B6-L model mice were also
assessed. Compared to the vehicle group, KSY and co-
treatment did not induce significant differences in body
weights (Figure 8b) or in the serum levels of AST and
creatinine (Figure 8c). These biochemical values were
within the normal ranges described in the Mouse Phe-
nome Database [28]. Therefore, KSY treatment along or
combination with Lipo-Dox did not induce significant
hepatic and renal toxicity in B6-L model mice.
Discussion
KSY treatment delayed tumor growth in both immuno-
competent and immunocompromised tumor-bearing
mice (Figure 2), indicating that KSY could impair tumorgrowth with or without an intact immune system. The
tumor-suppressive effects of KSY in immunocompromised
hosts further validated that KSY had direct inhibitory ef-
fects on tumor cells. In tumor-bearing immunocompetent
mice, neither the number of tumor infiltrated lymphocytes
nor the anti-cancer cytokines were increased after KSY
treatment (Figure 3). Collectively, the data showed that the
potential anticancer activity of KSY acted mainly through
the suppression of bladder cancer cells rather than the
stimulation of anticancer immunity (Figures 2 and 3).
The immune cells in tumor microenvironment have
been found to modulate tumor progression [29]. Induc-
tion of anticancer immunity is considered as a promising
strategy for cancer therapy [30,31]. Several ingredients
of KSY have been previously demonstrated to exhibit
immunomodulatory activity in pre-clinical studies [10-19].
Conversely, our data showed that KSY did not appear to
induce immunity in these models and the anticancer activ-
ity of KSY is independent of the immune modulation
(Figures 2 and 3). The discrepancy between these obser-
vations and previous reports regarding the immune-
modulating effects may result from differences in the
dosages, the experimental conditions used, the extraction
Figure 8 The tumor-suppressive effects and toxicity assessments in a lung cancer model. (a) The experimental protocol of lung cancer
model (B6-L model in Figure 1) was performed and the tumor volumes were measured (n = 15-17 for each treatment group). (b) The body
weights from all treatment groups are shown. (c) The serum biochemical data, from treatment groups or from healthy mice, were measured.
The serum data from healthy mice (n = 3) serves as reference values: AST: 25.3 ± 3.5 U/L; ALT: 33.3 ± 2.1 U/L; BUN: 30.7 ± 1.4 mg/dL; Creatinine:
0.3 ± 0.1 mg/dL. *indicates p < 0.05 versus vehicle or healthy group.
Figure 7 KSY did not cause toxic effects in immunocompetent tumor-bearing mice. The experimental protocol of bladder cancer cell (C3-B
model in Figure 1) was performed. The body weights (a) and serum biochemical data (b) from various treatment groups were shown. n = 18-21
for each group. The serum data from healthy mice (n = 9-10) serves as reference values: AST: 30.9 ± 5.7 U/L; ALT: 34.1 ± 9.0 U/L; BUN: 21.2 ± 3.4 mg/dL;
Creatinine: 0.2 ± 0.1 mg/dL.
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possible synergistic or buffering interactions between
these herbs may exist; thus, the pharmacological effects
of KSY may be more complex and different from the ef-
fects of one single herb.
The inhibitory effects of KSY on cancer cells in vivo
primarily resulted from the impairment of proliferation
rather than the enhancement of apoptosis (Figures 4
and 5). Such growth-suppressive effects of KSY might
be related to the increased expression of p53 and p21
(Figure 4). Both p53 and p21 are well-documented tumor
suppressors and p21 is a known downstream gene of p53.
The expression of p53 and p21 could be induced in re-
sponse to various cellular stresses, leading to the down-
regulation of cyclin-dependent kinases to impair cell cycle
progression [32]. Although the induction of p21 and p53
has also been reported to promote apoptosis of cancer
cells [33,34], such correlation were not observed in the
in vivo data (Figure 5). In line with the in vivo findings,
direct treatment of bladder tumor cells with KSY led to
cytostasis, in which both DNA synthesis and cell cycle
progression were impaired (Figure 6). Based on afore-
mentioned observation, growth suppression is the major
anticancer effect of KSY, which was different from the
immune-chemotherapeutic effects of OK432 [35] and
the cytotoxic effects of Lipo-dox [36]. Multiple molecular
mechanisms have been proposed to modulate the p53-
controlled target gene selection and cell fate determin-
ation [37]. It remains to be clarified whether KSY treat-
ment triggers any of these regulatory mechanisms to
specifically promote p53-dependent growth inhibition.
In clinical trial, KSY administration had been proven
to improve quality of life and hepatic function in Hepa-
titis B inactive carriers without causing major adverse ef-
fects [9]. In this study, KSY treatment at a dosage
comparable to that used in clinical study induced neither
hepatic injury or nephrotoxicity in bladder or lung can-
cer mouse models whether combination with chemo-
therapy or not (Figures 7 and 8). Qi-promoting herbal
medicine, such as KSY in this study, is traditionally con-
sidered to function as adjuvant for chemotherapeutic
drugs [38,39]. Nevertheless, our data indicated that KSY
did not enhance the therapeutic effect of chemotherapy
drug doxorubicin (Figure 8). Since the combined treat-
ment in our study was carried out in limited experimen-
tal conditions, the potential beneficial effects of KSY in
combined with chemotherapy certainly merit further ex-
tensive investigation.
Conclusions
In this study, the anticancer potential and the safety of
KSY were demonstrated, and the possible anticancer
mechanism of KSY was through the suppression of cancer
cell proliferation, instead of immunomodulation effects.Until now, few studies have described the pharmacological
activity of KSY, and this study is the first to reveal the po-
tential tumor-suppressive effects of KSY using murine
cancer models. In the future, more studies are warranted
to further explore the therapeutic effect, action mechan-
ism and herb-drug interactions of KSY with conventional
cancer therapeutics.
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